{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:56:35Z","timestamp":1790402195884,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Krembil Foundation and a Canadian Institutes of Health Research (CIHR)"},{"name":"The Psoriatic Arthritis Program is funded in part by The Arthritis Society, CIHR, and the Krembil Foundation."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate the incidence of psoriatic arthritis (PsA) in patients with psoriasis, and to identify risk factors for its development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was designed as a prospective cohort study involving psoriasis patients who did not have a diagnosis of arthritis at the time of study enrollment. Information was collected about lifestyle habits, comorbidities, psoriasis activity, and medications. Patients who developed inflammatory arthritis or spondylitis were classified as having PsA if they fulfilled the criteria of the Classification of Psoriatic Arthritis Study group. The annual incidence of PsA was estimated using an event per person\u2010years analysis. Cox proportional hazards models, involving fixed and time\u2010dependent explanatory variables, were fitted to obtain estimates of the relative risk (RR) of the onset of PsA, determined in multivariate models stratified by sex and controlled for age at onset of psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The data obtained from the 464 patients who were followed up for 8 years were analyzed. A total of 51 patients developed PsA during the 8 years since enrollment. The annual incidence rate of PsA was 2.7 cases (95% confidence interval 2.1\u20133.6) per 100 psoriasis patients. The following baseline variables were associated with the development of PsA in multivariate analysis: severe psoriasis (RR 5.4, <jats:italic>P<\/jats:italic>\u2009=\u20090.006), low level of education (university\/college versus high school incomplete RR 0.22, <jats:italic>P<\/jats:italic>\u2009=\u20090.005; high school graduate versus high school incomplete RR 0.30, <jats:italic>P<\/jats:italic>\u2009=\u20090.049), and use of retinoid medications (RR 3.4, <jats:italic>P<\/jats:italic>\u2009=\u20090.02). In multivariate models with time\u2010dependent variables, psoriatic nail pitting (RR 2.5, <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and uveitis (RR 31.5, <jats:italic>P<\/jats:italic>\u2009=\u20090.0002) were associated with the development of PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of PsA in patients with psoriasis is higher than previously reported. A severe psoriasis phenotype, presence of nail pitting, low level of education, and uveitis are predictive of the development of PsA in patients with psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.39494","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T13:58:59Z","timestamp":1447163939000},"page":"915-923","source":"Crossref","is-referenced-by-count":281,"title":["The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study"],"prefix":"10.1002","volume":"68","author":[{"given":"Lihi","family":"Eder","sequence":"first","affiliation":[{"name":"Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Haddad","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl F.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ker\u2010Ai","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Waterloo Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cook","sequence":"additional","affiliation":[{"name":"University of Waterloo Waterloo Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201706"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24172"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03463.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20401"},{"key":"e_1_2_6_8_1","volume-title":"Psoriasis: assessment and management. NICE guidelines CG153; October 2012","author":"National Institute for Health and Clinical Excellence (UK)","year":"2012"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12560"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13272"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03985.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes324"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201299"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201273"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20496"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073932"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080668"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00745.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089441"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_6_23_1","volume-title":"SF\u201036 health survey: manual and interpretation guide","author":"Ware JE","year":"1993"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24608"},{"key":"e_1_2_6_28_1","first-page":"2577","article-title":"Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire","volume":"29","author":"Alenius GM","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.010"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000182250"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111298"},{"key":"e_1_2_6_32_1","first-page":"484","article-title":"An analysis of 372 patients with anterior uveitis in a large Ibero\u2010American cohort of spondyloarthritis: the RESPONDIA Group","volume":"31","author":"Sampaio\u2010Barros PD","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.1.67"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962012000600009"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23704"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205461"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39494","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:03:55Z","timestamp":1759953835000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/art.39494"],"URL":"https:\/\/doi.org\/10.1002\/art.39494","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}